Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ji-Jing Pang

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Molecular Genetics & Genomic Medicine|February 24, 2025
Unveiling the Genetic and Phenotypic Landscape of a Chinese Cohort With Retinitis PigmentosaHe-Nan Sun, Kai-Li Du, Yan Sun, et al.
Human Molecular Genetics|April 10, 2015
Vitreal delivery of AAV vectored Cnga3 restores cone function in CNGA3-/-/Nrl-/- mice, an all-cone model of CNGA3 achromatopsiaWei Du, Ye Tao, Wen-Tao Deng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 4, 2010
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retinaHilda Petrs-Silva, Astra Dinculescu, Qiuhong Li, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 15, 2005
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosisJi-jing Pang, Bo Chang, Ashok Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 24, 2008
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsArtur V Cideciyan, Tomas S Aleman, Sanford L Boye, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 14, 2011
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 yearsSamuel G Jacobson, Artur V Cideciyan, Ramakrishna Ratnakaram, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Molecular Genetics & Genomic Medicine|February 24, 2025
Unveiling the Genetic and Phenotypic Landscape of a Chinese Cohort With Retinitis PigmentosaHe-Nan Sun, Kai-Li Du, Yan Sun, et al.
Human Molecular Genetics|April 10, 2015
Vitreal delivery of AAV vectored Cnga3 restores cone function in CNGA3-/-/Nrl-/- mice, an all-cone model of CNGA3 achromatopsiaWei Du, Ye Tao, Wen-Tao Deng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 4, 2010
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retinaHilda Petrs-Silva, Astra Dinculescu, Qiuhong Li, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 15, 2005
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosisJi-jing Pang, Bo Chang, Ashok Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 24, 2008
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsArtur V Cideciyan, Tomas S Aleman, Sanford L Boye, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 14, 2011
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 yearsSamuel G Jacobson, Artur V Cideciyan, Ramakrishna Ratnakaram, et al.
Pageof 4